An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023-Reference-Cited by-同舟云学术

An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023

Published:2018-07-31 Issue:1 Volume:18 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Shoji Tadahiro, ,Komiyama Shinichi,Kigawa Junzo,Tanabe Hiroshi,Kato Kazuyoshi,Itamochi Hiroaki,Fujiwara Hiroyuki,Kamiura Shoji,Hamano Tetsutaro,Sugiyama Toru

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-018-4505-4.pdf

Reference34 articles.

1. Nakaji S, Umeda T, Takahashi I, Matsuzaka M, Iwane K. Epidemiological features of ovarian cancer in Japan and the world. Nihon Rinsho. 2012;70:459–64.

2. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33:S3–11.

3. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419–25.

4. Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16:561–8.

5. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22:3120–5.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-07-05

2. Effect of prior cancer history on survival of patients with esophageal carcinoma: a propensity score matching, population-based study;Journal of Thoracic Disease;2022-04

3. Bruceine D Sensitizes Human Ovarian Cancer Cells to Paclitaxel Through JNK and STAT3 Signal Regulation;Revista Brasileira de Farmacognosia;2022-03-26

4. Two cases showing the effects of bevacizumab on recurrent cervical cancer with pleural effusion;International Cancer Conference Journal;2022-03-16

5. Antitumor effect of isoquercetin on tissue vasohibin expression and colon cancer vasculature;Oncotarget;2022-02-08